Phibro Animal Health (PAHC) Financials

$24.58 -0.08 (-0.32%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$24.41 -0.17 (-0.69%)

As of 05/30/2025 04:21 PM Eastern

Annual Income Statements for Phibro Animal Health

This table shows Phibro Animal Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	6/30/2024	6/30/2023	6/30/2022	6/30/2021	6/30/2020	6/30/2019	6/30/2018	6/30/2017	6/30/2016	6/30/2015	6/30/2014
Net Income / (Loss) Attributable to Common Shareholders	2.42	33	49	54	34	55	65	65	83	60	-3.13
Consolidated Net Income / (Loss)	2.42	33	49	54	34	55	65	65	83	60	-3.13
Net Income / (Loss) Continuing Operations	2.42	33	49	54	34	55	65	65	83	60	-3.13
Total Pre-Tax Income	11	54	72	66	56	72	88	81	77	79	6.31
Total Operating Income	53	72	79	75	69	83	99	98	86	88	64
Total Gross Profit	313	298	285	271	257	265	267	248	239	233	204
Total Revenue	1,018	978	942	833	800	828	820	764	752	749	692
Operating Revenue	1,018	978	942	833	800	828	820	764	752	749	692
Total Cost of Revenue	705	680	657	562	543	563	553	516	512	515	488
Operating Cost of Revenue	705	680	657	562	543	563	553	516	512	515	488
Total Operating Expenses	260	226	206	197	188	181	168	150	153	146	141
Selling, General & Admin Expense	260	226	206	197	188	181	168	150	153	146	141
Total Other Income / (Expense), net	-42	-18	-6.66	-8.40	-14	-12	-11	-17	-8.98	-8.91	-57
Interest & Investment Income	-19	-15	-12	-	-	-	-	-	-	-	-
Other Income / (Expense), net	-24	-2.46	5.22	4.48	-0.83	0.06	1.05	0.11	7.61	5.40	-1.75
Income Tax Expense	8.50	21	23	12	22	17	23	16	-5.97	18	9.44
Basic Earnings per Share	$0.06	$0.81	$1.21	$1.34	$0.83	$1.35	$1.61	$1.63	$2.11	$1.55	($0.10)
Weighted Average Basic Shares Outstanding	40.50M	40.50M	40.50M	40.47M	40.45M	40.41M	40.18M	39.52M	39.25M	38.97M	32.19M
Diluted Earnings per Share	$0.06	$0.81	$1.21	$1.34	$0.83	$1.35	$1.61	$1.61	$2.07	$1.51	($0.10)
Weighted Average Diluted Shares Outstanding	40.52M	40.50M	40.50M	40.50M	40.50M	40.52M	40.39M	40.04M	39.96M	39.82M	32.19M
Weighted Average Basic & Diluted Shares Outstanding	40.50M	40.50M	40.50M	40.50M	40.45M	40.45M	40.30M	39.60M	39.20M	38.90M	31.30M
Cash Dividends to Common per Share	$0.48	$0.48	$0.48	$0.48	$0.48	$0.46	$0.40	$0.40	$0.40	$0.40	$0.82

This table shows Phibro Animal Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	21	3.19	6.98	0.75	8.41	1.27	-8.02	11	10	7.21	3.86
Consolidated Net Income / (Loss)	21	3.19	6.98	0.75	8.41	1.27	-8.02	11	10	7.21	3.86
Net Income / (Loss) Continuing Operations	21	3.19	6.98	0.75	8.41	1.27	-8.02	11	10	7.21	3.86
Total Pre-Tax Income	30	4.84	9.62	6.41	13	3.57	-12	21	15	12	5.42
Total Operating Income	34	26	18	18	20	16	-0.73	24	19	16	14
Total Gross Profit	105	102	83	87	80	79	68	77	76	77	69
Total Revenue	348	309	260	273	263	250	231	255	246	245	233
Operating Revenue	348	309	260	273	263	250	231	255	246	245	233
Total Cost of Revenue	243	207	177	186	184	171	164	178	170	167	164
Operating Cost of Revenue	243	207	177	186	184	171	164	178	170	167	164
Total Operating Expenses	71	76	66	69	60	63	68	53	57	62	55
Selling, General & Admin Expense	71	76	66	69	60	63	68	53	57	62	55
Total Other Income / (Expense), net	-3.83	-21	-8.08	-12	-7.00	-12	-11	-2.33	-3.45	-3.74	-8.27
Interest & Investment Income	-9.36	-9.00	-7.64	-	-	-4.66	-4.56	-	-	-	-
Other Income / (Expense), net	5.53	-12	-0.44	-7.27	-2.43	-7.48	-6.69	2.17	0.42	0.15	-5.20
Income Tax Expense	8.81	1.65	2.65	5.66	4.52	2.29	-3.96	9.94	5.06	4.90	1.56
Basic Earnings per Share	$0.52	$0.08	$0.17	$0.02	$0.21	$0.03	($0.20)	$0.28	$0.25	$0.18	$0.10
Weighted Average Basic Shares Outstanding	40.52M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M
Diluted Earnings per Share	$0.51	$0.08	$0.17	$0.02	$0.21	$0.03	($0.20)	$0.28	$0.25	$0.18	$0.10
Weighted Average Diluted Shares Outstanding	40.71M	40.72M	40.58M	40.52M	40.52M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M
Weighted Average Basic & Diluted Shares Outstanding	40.53M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M
Cash Dividends to Common per Share	$0.12	$0.12	$0.12	-	$0.12	$0.12	$0.12	-	$0.12	$0.12	$0.12

This table details how cash moves in and out of Phibro Animal Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	6/30/2024	6/30/2023	6/30/2022	6/30/2021	6/30/2020	6/30/2019	6/30/2018	6/30/2017	6/30/2016	6/30/2015	6/30/2014
Net Change in Cash & Equivalents	29	-33	24	14	-21	28	-27	22	4.39	17	-16
Net Cash From Operating Activities	88	13	32	48	59	47	70	98	37	69	-0.71
Net Cash From Continuing Operating Activities	88	13	32	48	59	47	70	98	37	69	-0.71
Net Income / (Loss) Continuing Operations	2.42	33	49	54	34	55	65	65	83	60	-3.13
Consolidated Net Income / (Loss)	2.42	33	49	54	34	55	65	65	83	60	-3.13
Depreciation Expense	36	34	33	32	32	28	27	26	23	22	21
Amortization Expense	1.04	0.73	0.59	0.83	0.88	0.88	0.88	1.02	0.99	0.97	1.45
Non-Cash Adjustments To Reconcile Net Income	27	-10	-5.38	-6.75	-1.90	0.06	4.79	6.28	-1.65	-1.96	6.46
Changes in Operating Assets and Liabilities, net	21	-44	-45	-32	-5.53	-36	-27	0.48	-68	-12	-27
Net Cash From Investing Activities	-48	-74	-23	-19	-120	-14	-85	-22	-83	-34	-19
Net Cash From Continuing Investing Activities	-48	-74	-23	-19	-120	-14	-85	-22	-83	-34	-19
Purchase of Property, Plant & Equipment	-41	-52	-37	-29	-34	-30	-19	-21	-36	-20	-20
Acquisitions	-3.28	0.00	-14	0.00	-55	-9.84	-15	-	-47	-10	-
Purchase of Investments	-66	-40	-64	-74	-80	-34	-82	-	-	-	-
Sale and/or Maturity of Investments	62	17	91	86	49	60	32	-	-	-	-
Other Investing Activities, net	0.33	0.78	0.62	-1.26	-0.80	-0.40	-1.06	-1.06	0.14	-4.03	0.43
Net Cash From Financing Activities	-6.77	27	16	-17	41	-4.11	-12	-54	50	-15	4.78
Net Cash From Continuing Financing Activities	-6.77	27	16	-17	41	-4.11	-12	-54	50	-15	4.78
Repayment of Debt	-263	-280	-256	-298	-183	-203	-226	-524	-193	-39	-549
Payment of Dividends	-19	-19	-19	-19	-19	-19	-16	-16	-16	-16	-25
Issuance of Debt	276	326	297	300	243	217	225	481	256	38	465
Other Financing Activities, net	0.00	0.00	-4.84	0.00	0.00	-	-	-	-	-	-
Effect of Exchange Rate Changes	-3.30	0.75	-1.37	1.14	-1.12	-0.52	-0.54	-0.23	-0.42	-1.49	-0.20
Cash Interest Paid	17	15	11	11	12	12	11	15	14	13	45
Cash Income Taxes Paid	15	20	18	19	21	16	15	15	17	11	12

This table details how cash moves in and out of Phibro Animal Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-6.72	15	-19	20	17	-10	1.87	4.04	-31	-7.86	2.03
Net Cash From Operating Activities	43	3.08	13	28	11	32	16	20	6.26	-2.49	-11
Net Cash From Continuing Operating Activities	43	3.08	13	28	11	32	16	20	6.26	-2.49	-11
Net Income / (Loss) Continuing Operations	21	3.19	6.98	0.75	8.41	1.27	-8.02	11	10	7.21	3.86
Consolidated Net Income / (Loss)	21	3.19	6.98	0.75	8.41	1.27	-8.02	11	10	7.21	3.86
Depreciation Expense	13	12	9.00	9.20	9.20	8.91	8.87	8.57	8.49	8.50	8.45
Amortization Expense	0.57	0.50	0.37	0.26	0.26	0.26	0.26	0.21	0.19	0.18	0.15
Non-Cash Adjustments To Reconcile Net Income	1.28	13	-0.80	2.56	4.12	5.53	15	-3.84	-4.65	-4.64	3.06
Changes in Operating Assets and Liabilities, net	7.81	-25	-2.93	16	-11	16	0.40	3.79	-7.81	-14	-26
Net Cash From Investing Activities	-18	-260	-2.93	-9.11	1.13	-25	-15	-10	-38	-9.81	-16
Net Cash From Continuing Investing Activities	-18	-260	-2.93	-9.11	1.13	-25	-15	-10	-38	-9.81	-16
Purchase of Property, Plant & Equipment	-7.75	-7.82	-9.58	-13	-9.73	-11	-7.48	-11	-7.91	-9.82	-23
Acquisitions	-1.05	-	-	-	0.04	-	-	-	-	-	-
Purchase of Investments	-10	-	0.00	-	-6.00	-43	-17	-	-30	-10	0.00
Other Investing Activities, net	0.55	0.17	0.65	-0.56	-0.18	0.95	0.12	0.61	0.13	0.01	0.03
Net Cash From Financing Activities	-32	276	-29	1.79	4.85	-15	1.30	-6.33	0.28	3.72	29
Net Cash From Continuing Financing Activities	-32	276	-29	1.79	4.85	-15	1.30	-6.33	0.28	3.72	29
Repayment of Debt	-107	-198	-589	-114	-56	-50	-43	-86	-27	-126	-40
Payment of Dividends	-4.87	-4.86	-4.86	-4.86	-4.86	-4.86	-4.86	-4.86	-4.86	-4.86	-4.86
Issuance of Debt	81	481	567	121	62	42	51	85	32	135	74
Other Financing Activities, net	-1.30	-1.95	-1.95	-	-	-1.74	-1.74	-	-	-	0.00
Effect of Exchange Rate Changes	0.60	-3.69	0.73	-0.72	-0.14	-2.18	-0.27	0.42	0.05	0.73	-0.44

This table presents Phibro Animal Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	6/30/2024	6/30/2023	6/30/2022	6/30/2021	6/30/2020	6/30/2019	6/30/2018	6/30/2017	6/30/2016	6/30/2015	6/30/2014
Total Assets	982	971	932	841	784	727	672	623	608	493	472
Total Current Assets	601	586	566	499	452	466	415	364	343	314	299
Cash & Equivalents	71	41	74	50	36	58	29	56	34	29	12
Short-Term Investments	44	40	17	43	55	24	50	-	-	-	-
Accounts Receivable	169	163	167	147	127	159	136	126	124	111	114
Inventories, net	266	278	259	216	197	198	178	161	168	150	143
Other Current Assets	51	63	49	43	37	27	22	21	18	24	-
Plant, Property, & Equipment, net	203	196	165	155	148	140	130	127	127	104	109
Total Noncurrent Assets	178	190	200	188	184	120	126	132	138	75	64
Goodwill	55	53	53	53	53	27	27	24	21	13	-
Intangible Assets	45	55	64	62	71	47	52	55	60	37	30
Other Noncurrent Operating Assets	78	82	83	73	60	45	47	54	56	25	34
Total Liabilities & Shareholders' Equity	982	971	932	841	784	727	672	623	608	493	472
Total Liabilities	726	689	669	603	596	511	487	472	517	464	457
Total Current Liabilities	204	176	191	164	157	154	143	116	109	111	112
Short-Term Debt	30	22	15	9.38	19	13	13	6.25	2.91	2.81	2.97
Accounts Payable	86	74	96	68	66	73	59	57	60	63	60
Accrued Expenses	89	80	80	86	72	68	71	53	46	45	50
Total Noncurrent Liabilities	521	513	478	439	439	356	344	356	409	352	345
Long-Term Debt	458	453	418	383	368	314	300	307	347	287	286
Other Noncurrent Operating Liabilities	63	60	61	56	70	43	44	50	61	66	58
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	257	283	262	239	188	216	185	151	90	30	15
Total Preferred & Common Equity	257	283	262	239	188	216	185	151	90	30	15
Preferred Stock	0.00	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	257	283	262	239	188	216	185	151	90	30	15
Common Stock	136	136	136	136	136	133	130	124	118	118	132
Retained Earnings	244	261	248	218	183	169	132	83	34	-37	-97
Accumulated Other Comprehensive Income / (Loss)	-124	-114	-121	-115	-130	-86	-76	-55	-62	-52	-20

This table presents Phibro Animal Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2025	Q2 2025	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	3/31/2024	12/31/2023	9/30/2023	3/31/2023	12/31/2022	9/30/2022	3/31/2022
Total Assets	1,317	1,286	966	979	973	965	965	962	948	916
Total Current Assets	776	746	571	597	587	584	585	582	570	546
Cash & Equivalents	60	67	52	50	33	43	37	68	76	71
Short-Term Investments	10	0.00	38	49	60	48	40	10	10	22
Accounts Receivable	198	192	161	161	151	149	153	152	143	157
Inventories, net	448	427	273	282	287	279	293	289	281	250
Other Current Assets	60	60	48	55	57	65	63	62	60	47
Plant, Property, & Equipment, net	336	338	206	202	201	193	189	186	179	162
Total Noncurrent Assets	205	202	189	180	185	187	191	194	199	207
Goodwill	55	55	55	55	55	53	53	53	53	53
Intangible Assets	38	40	43	48	51	52	57	59	61	67
Other Noncurrent Operating Assets	113	107	92	77	80	81	81	82	85	87
Total Liabilities & Shareholders' Equity	1,317	1,286	966	979	973	965	965	962	948	916
Total Liabilities	1,051	1,039	708	709	702	691	693	693	686	649
Total Current Liabilities	266	233	177	189	188	172	165	168	172	187
Short-Term Debt	16	16	7.50	30	26	24	15	15	15	15
Accounts Payable	132	99	87	83	86	77	76	80	88	90
Accrued Expenses	119	118	83	77	75	71	74	72	69	82
Total Noncurrent Liabilities	785	805	531	520	514	519	528	526	513	462
Long-Term Debt	711	737	467	456	449	459	466	461	452	401
Other Noncurrent Operating Liabilities	74	69	64	64	65	60	62	65	61	62
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	266	247	259	270	271	273	272	268	263	267
Total Preferred & Common Equity	266	247	259	270	271	273	272	268	263	267
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	266	247	259	270	271	273	272	268	263	267
Common Stock	137	137	136	136	136	136	136	136	136	136
Retained Earnings	260	244	246	248	244	248	254	249	247	245
Accumulated Other Comprehensive Income / (Loss)	-131	-134	-124	-114	-110	-111	-118	-117	-120	-114

This table displays calculated financial ratios and metrics derived from Phibro Animal Health's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	6/30/2024	6/30/2023	6/30/2022	6/30/2021	6/30/2020	6/30/2019	6/30/2018	6/30/2017	6/30/2016	6/30/2015	6/30/2014
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	4.07%	3.78%	13.07%	4.12%	-3.34%	0.98%	7.29%	1.70%	0.39%	8.19%	5.93%
EBITDA Growth	-35.97%	-11.38%	4.85%	10.31%	-9.07%	-12.58%	2.19%	6.17%	1.86%	36.14%	14.13%
EBIT Growth	-57.56%	-17.59%	6.12%	16.06%	-17.91%	-16.70%	1.97%	5.03%	0.31%	50.01%	16.01%
NOPAT Growth	-72.76%	-19.32%	-12.33%	46.47%	-34.33%	-12.62%	-7.24%	-14.98%	37.73%	312.17%	-139.97%
Net Income Growth	-92.59%	-33.69%	-9.58%	62.09%	-38.68%	-15.67%	0.41%	-21.89%	37.24%	2,027.73%	-112.56%
EPS Growth	-92.59%	-33.06%	-9.70%	61.45%	-38.52%	-16.15%	0.00%	-22.22%	37.09%	1,610.00%	-112.20%
Operating Cash Flow Growth	558.11%	-57.95%	-34.48%	-18.61%	25.82%	-32.62%	-28.84%	164.35%	-45.83%	9,749.44%	83.58%
Free Cash Flow Firm Growth	301.79%	-119.91%	-268.50%	-58.41%	-12.53%	-66.26%	-18.70%	413.26%	-135.36%	226.96%	71.06%
Invested Capital Growth	-6.80%	11.91%	12.41%	11.06%	5.05%	10.15%	2.44%	0.29%	40.39%	-0.95%	8.70%
Revenue Q/Q Growth	1.81%	-0.02%	3.86%	4.31%	-2.20%	-0.95%	2.11%	0.75%	0.57%	0.17%	0.00%
EBITDA Q/Q Growth	-17.48%	11.45%	-3.32%	0.44%	8.47%	-10.93%	2.96%	0.06%	3.69%	5.38%	0.00%
EBIT Q/Q Growth	-33.44%	17.76%	-5.15%	1.10%	11.28%	-14.34%	3.30%	0.46%	3.38%	7.03%	0.00%
NOPAT Q/Q Growth	-60.34%	-3.93%	-7.68%	29.03%	-12.83%	-17.38%	6.39%	4.91%	2.09%	22.16%	0.00%
Net Income Q/Q Growth	-81.64%	14.03%	-16.38%	26.75%	-8.61%	-19.58%	11.59%	0.25%	6.18%	87.01%	0.00%
EPS Q/Q Growth	-81.25%	14.08%	-16.55%	25.23%	-7.78%	-20.12%	13.38%	-1.23%	7.25%	122.06%	0.00%
Operating Cash Flow Q/Q Growth	10.32%	348.60%	-4.51%	-1.64%	-15.64%	11.25%	-4.72%	-11.68%	14.56%	110.75%	-103.81%
Free Cash Flow Firm Q/Q Growth	17.58%	31.39%	54.34%	-69.19%	-26.92%	-44.68%	29.21%	-11.25%	22.48%	0.00%	0.00%
Invested Capital Q/Q Growth	-4.12%	-0.07%	2.44%	6.83%	0.67%	0.56%	-0.29%	2.16%	-1.18%	0.15%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	30.77%	30.50%	30.29%	32.56%	32.10%	31.96%	32.55%	32.48%	31.81%	31.16%	29.54%
EBITDA Margin	6.55%	10.65%	12.47%	13.45%	12.69%	13.49%	15.59%	16.36%	15.67%	15.45%	12.28%
Operating Margin	5.24%	7.35%	8.38%	8.98%	8.65%	10.05%	12.06%	12.81%	11.41%	11.71%	9.22%
EBIT Margin	2.89%	7.10%	8.94%	9.52%	8.54%	10.06%	12.19%	12.83%	12.42%	12.43%	8.97%
Profit (Net Income) Margin	0.24%	3.33%	5.22%	6.53%	4.19%	6.61%	7.91%	8.45%	11.01%	8.05%	-0.45%
Tax Burden Percent	22.13%	60.30%	67.99%	81.82%	60.44%	76.52%	73.67%	80.22%	107.77%	76.53%	-49.57%
Interest Burden Percent	37.06%	77.92%	85.90%	83.77%	81.20%	85.86%	88.09%	82.15%	82.23%	84.63%	10.17%
Effective Tax Rate	77.87%	39.70%	32.01%	18.18%	39.56%	23.48%	26.33%	19.78%	-7.77%	23.47%	149.57%
Return on Invested Capital (ROIC)	1.81%	6.77%	9.41%	12.00%	8.86%	14.49%	17.64%	19.27%	26.52%	23.03%	-11.25%
ROIC Less NNEP Spread (ROIC-NNEP)	-0.64%	3.85%	8.00%	9.68%	5.79%	10.74%	14.38%	14.41%	23.16%	20.50%	-2.00%
Return on Net Nonoperating Assets (RNNOA)	-0.91%	5.20%	10.22%	13.49%	7.75%	12.80%	20.97%	34.21%	111.24%	246.21%	22.88%
Return on Equity (ROE)	0.90%	11.97%	19.63%	25.49%	16.60%	27.29%	38.61%	53.48%	137.76%	269.25%	11.63%
Cash Return on Invested Capital (CROIC)	8.84%	-4.47%	-2.28%	1.51%	3.93%	4.83%	15.23%	18.99%	-7.09%	23.99%	-19.59%
Operating Return on Assets (OROA)	3.02%	7.29%	9.50%	9.76%	9.05%	11.91%	15.44%	15.93%	16.96%	19.28%	13.11%
Return on Assets (ROA)	0.25%	3.43%	5.55%	6.69%	4.44%	7.83%	10.02%	10.50%	15.03%	12.49%	-0.66%
Return on Common Equity (ROCE)	0.90%	11.97%	19.63%	25.49%	16.60%	27.29%	38.61%	53.48%	137.76%	269.25%	11.63%
Return on Equity Simple (ROE_SIMPLE)	0.94%	11.54%	18.74%	22.80%	17.83%	25.33%	35.08%	42.75%	91.43%	203.46%	-20.64%
Net Operating Profit after Tax (NOPAT)	12	43	54	61	42	64	73	79	92	67	-32
NOPAT Margin	1.16%	4.43%	5.70%	7.35%	5.23%	7.69%	8.89%	10.28%	12.30%	8.96%	-4.57%
Net Nonoperating Expense Percent (NNEP)	2.45%	2.92%	1.41%	2.31%	3.06%	3.75%	3.26%	4.86%	3.36%	2.53%	-9.26%
Cost of Revenue to Revenue	69.23%	69.50%	69.71%	67.44%	67.90%	68.04%	67.45%	67.52%	68.19%	68.84%	70.46%
SG&A Expenses to Revenue	25.53%	23.15%	21.91%	23.58%	23.45%	21.91%	20.48%	19.67%	20.40%	19.45%	20.32%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	25.53%	23.15%	21.91%	23.58%	23.45%	21.91%	20.48%	19.67%	20.40%	19.45%	20.32%
Earnings before Interest and Taxes (EBIT)	29	69	84	79	68	83	100	98	93	93	62
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	67	104	117	112	102	112	128	125	118	116	85
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.65	1.90	2.75	4.47	5.04	5.20	8.65	8.29	6.83	42.50	45.93
Price to Tangible Book Value (P/TBV)	4.33	3.07	4.97	8.63	14.69	7.95	15.15	17.26	66.76	0.00	0.00
Price to Revenue (P/Rev)	0.67	0.55	0.77	1.28	1.18	1.36	1.95	1.64	0.82	1.68	1.01
Price to Earnings (P/E)	281.14	16.42	14.68	19.60	28.25	20.53	24.66	19.38	7.48	20.89	0.00
Dividend Yield	2.86%	3.63%	2.69%	1.82%	2.05%	1.66%	1.01%	1.27%	2.55%	1.24%	0.00%
Earnings Yield	0.36%	6.09%	6.81%	5.10%	3.54%	4.87%	4.05%	5.16%	13.38%	4.79%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.67	1.37	1.76	2.54	2.57	2.97	4.38	3.70	2.30	5.24	3.33
Enterprise Value to Revenue (EV/Rev)	1.03	0.95	1.13	1.64	1.55	1.65	2.24	1.98	1.24	2.03	1.41
Enterprise Value to EBITDA (EV/EBITDA)	15.79	8.92	9.05	12.18	12.24	12.24	14.35	12.07	7.94	13.14	11.46
Enterprise Value to EBIT (EV/EBIT)	35.74	13.39	12.63	17.20	18.19	16.42	18.34	15.40	10.02	16.33	15.69
Enterprise Value to NOPAT (EV/NOPAT)	89.21	21.44	19.81	22.28	29.73	21.48	25.16	19.21	10.12	22.64	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	12.02	69.79	33.61	28.25	20.95	29.00	26.19	15.34	25.12	22.11	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	18.23	0.00	0.00	176.70	66.95	64.42	29.14	19.50	0.00	21.74	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.90	1.68	1.65	1.64	2.06	1.51	1.69	2.07	3.87	9.77	19.10
Long-Term Debt to Equity	1.79	1.60	1.59	1.60	1.96	1.45	1.62	2.03	3.84	9.68	18.91
Financial Leverage	1.42	1.35	1.28	1.39	1.34	1.19	1.46	2.37	4.80	12.01	-11.45
Leverage Ratio	3.62	3.49	3.54	3.81	3.74	3.49	3.85	5.10	9.17	21.57	-17.60
Compound Leverage Factor	1.34	2.72	3.04	3.19	3.03	2.99	3.39	4.19	7.54	18.25	-1.79
Debt to Total Capital	65.54%	62.70%	62.26%	62.18%	67.28%	60.16%	62.81%	67.44%	79.47%	90.72%	95.03%
Short-Term Debt to Total Capital	4.00%	2.94%	2.16%	1.49%	3.26%	2.31%	2.53%	1.35%	0.66%	0.88%	0.97%
Long-Term Debt to Total Capital	61.54%	59.75%	60.10%	60.69%	64.02%	57.85%	60.28%	66.10%	78.81%	89.84%	94.05%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	34.46%	37.30%	37.74%	37.82%	32.72%	39.84%	37.19%	32.56%	20.53%	9.28%	4.97%
Debt to EBITDA	7.32	4.56	3.68	3.50	3.81	2.92	2.44	2.50	2.97	2.50	3.41
Net Debt to EBITDA	5.60	3.78	2.91	2.67	2.91	2.19	1.82	2.06	2.69	2.25	3.27
Long-Term Debt to EBITDA	6.87	4.35	3.56	3.42	3.62	2.81	2.35	2.45	2.95	2.48	3.37
Debt to NOPAT	41.36	10.96	8.06	6.40	9.25	5.12	4.29	3.99	3.79	4.32	-9.15
Net Debt to NOPAT	31.65	9.08	6.36	4.88	7.07	3.84	3.20	3.27	3.43	3.88	-8.78
Long-Term Debt to NOPAT	38.84	10.45	7.78	6.25	8.81	4.93	4.11	3.91	3.76	4.27	-9.06
Altman Z-Score	2.53	2.59	2.81	3.20	3.04	3.68	4.45	4.00	3.00	4.16	3.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.94	3.33	2.97	3.04	2.87	3.02	2.90	3.14	3.15	2.82	2.66
Quick Ratio	1.39	1.39	1.35	1.46	1.39	1.56	1.50	1.57	1.45	1.26	1.12
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	58	-29	-13	7.72	19	21	63	77	-25	70	-55
Operating Cash Flow to CapEx	212.41%	25.70%	85.44%	164.75%	174.32%	157.80%	377.44%	471.19%	102.38%	342.53%	-3.59%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.60	1.44	1.80	5.28	4.42	-1.49	4.89	-0.99
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	3.75	4.62	4.01	5.88	5.62	2.24	4.80	-0.01
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	1.47	1.97	1.47	4.32	4.43	0.05	3.40	-0.37
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.04	1.03	1.06	1.03	1.06	1.18	1.27	1.24	1.37	1.55	1.46
Accounts Receivable Turnover	6.11	5.93	6.01	6.10	5.61	5.62	6.27	6.12	6.40	6.66	6.50
Inventory Turnover	2.59	2.53	2.76	2.72	2.75	2.99	3.26	3.14	3.23	3.52	3.44
Fixed Asset Turnover	5.10	5.42	5.89	5.50	5.55	6.13	6.37	6.00	6.49	7.01	6.48
Accounts Payable Turnover	8.84	8.02	8.01	8.36	7.80	8.49	9.50	8.82	8.32	8.40	8.30
Days Sales Outstanding (DSO)	59.70	61.59	60.70	59.87	65.11	64.97	58.22	59.61	57.04	54.84	56.18
Days Inventory Outstanding (DIO)	140.77	144.12	132.10	134.11	132.64	121.96	111.99	116.33	113.05	103.76	106.02
Days Payable Outstanding (DPO)	41.29	45.50	45.55	43.66	46.77	42.98	38.40	41.40	43.88	43.44	43.99
Cash Conversion Cycle (CCC)	159.18	160.21	147.25	150.32	150.98	143.95	131.80	134.54	126.21	115.16	118.21
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	630	676	604	537	484	461	418	408	407	290	293
Invested Capital Turnover	1.56	1.53	1.65	1.63	1.69	1.88	1.98	1.87	2.16	2.57	2.46
Increase / (Decrease) in Invested Capital	-46	72	67	54	23	42	9.95	1.17	117	-2.79	23
Enterprise Value (EV)	1,053	929	1,064	1,365	1,243	1,368	1,834	1,510	935	1,519	973
Market Capitalization	679	535	722	1,066	948	1,123	1,600	1,252	618	1,259	696
Book Value per Share	$6.34	$6.97	$6.48	$5.89	$4.65	$5.34	$4.59	$3.81	$2.30	$0.76	$0.39
Tangible Book Value per Share	$3.88	$4.30	$3.59	$3.05	$1.60	$3.49	$2.62	$1.83	$0.24	($0.52)	($0.38)
Total Capital	745	757	695	631	575	542	497	464	441	319	305
Total Debt	488	475	433	392	387	326	312	313	350	290	289
Total Long-Term Debt	458	453	418	383	368	314	300	307	347	287	286
Net Debt	373	394	342	299	296	245	233	257	317	260	278
Capital Expenditures (CapEx)	41	52	37	29	34	30	19	21	36	20	20
Debt-free, Cash-free Net Working Capital (DFCFNWC)	312	351	299	251	222	243	206	198	203	176	178
Debt-free Net Working Capital (DFNWC)	427	432	390	344	313	324	285	254	237	205	190
Net Working Capital (NWC)	397	410	375	335	295	312	272	248	234	202	187
Net Nonoperating Expense (NNE)	9.38	11	4.53	6.87	8.27	8.97	8.00	14	9.68	6.82	-28
Net Nonoperating Obligations (NNO)	373	394	342	299	296	245	233	257	317	260	278
Total Depreciation and Amortization (D&A)	37	35	33	33	33	28	28	27	24	23	23
Debt-free, Cash-free Net Working Capital to Revenue	30.66%	35.87%	31.75%	30.11%	27.74%	29.34%	25.08%	25.91%	27.06%	23.51%	25.73%
Debt-free Net Working Capital to Revenue	41.92%	44.18%	41.43%	41.30%	39.15%	39.19%	34.73%	33.25%	31.53%	27.41%	27.43%
Net Working Capital to Revenue	39.00%	41.90%	39.84%	40.17%	36.81%	37.67%	33.20%	32.43%	31.14%	27.04%	27.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.06	$0.81	$1.21	$1.34	$0.83	$1.35	$1.61	$1.63	$2.11	$1.55	($0.10)
Adjusted Weighted Average Basic Shares Outstanding	40.50M	40.50M	40.50M	40.47M	40.45M	40.41M	40.18M	39.52M	39.25M	38.97M	38.96M
Adjusted Diluted Earnings per Share	$0.06	$0.81	$1.21	$1.34	$0.83	$1.35	$1.61	$1.61	$2.07	$1.51	($0.10)
Adjusted Weighted Average Diluted Shares Outstanding	40.52M	40.50M	40.50M	40.50M	40.50M	40.52M	40.39M	40.04M	39.96M	39.82M	38.96M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	($0.10)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	40.50M	40.50M	40.50M	40.50M	40.45M	40.45M	40.37M	39.89M	39.41M	39.10M	32.19M
Normalized Net Operating Profit after Tax (NOPAT)	37	43	54	61	42	64	73	79	60	67	45
Normalized NOPAT Margin	3.67%	4.43%	5.70%	7.35%	5.23%	7.69%	8.89%	10.28%	7.99%	8.96%	6.45%
Pre Tax Income Margin	1.07%	5.53%	7.68%	7.98%	6.94%	8.64%	10.74%	10.54%	10.21%	10.52%	0.91%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	6.16	5.32	7.07	8.39	5.60	5.63	6.51	1.11
NOPAT to Interest Expense	0.00	0.00	0.00	4.76	3.25	5.41	6.12	4.49	5.57	4.69	-0.57
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	3.88	2.67	4.53	6.84	4.41	3.44	5.10	0.76
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	2.48	0.60	2.87	4.56	3.30	3.38	3.29	-0.92
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	804.72%	59.63%	39.54%	35.73%	57.87%	33.98%	24.77%	24.49%	18.99%	25.87%	-799.49%
Augmented Payout Ratio	804.72%	59.63%	39.54%	35.73%	57.87%	33.98%	24.77%	24.49%	18.99%	25.87%	-799.49%

This table displays calculated financial ratios and metrics derived from Phibro Animal Health's official financial filings.

Metric	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	32.14%	23.73%	12.57%	7.10%	7.14%	2.17%	-0.50%	-0.08%	2.53%	5.13%	8.32%
EBITDA Growth	93.79%	48.97%	1,451.98%	-40.66%	-2.53%	-29.50%	-89.95%	44.52%	-27.90%	-28.76%	-16.62%
EBIT Growth	123.14%	68.22%	332.78%	-57.03%	-7.79%	-48.58%	-187.40%	67.60%	-36.24%	-39.61%	-32.04%
NOPAT Growth	81.89%	199.58%	2,625.13%	-83.04%	5.06%	-40.52%	-105.22%	-8.00%	-2.51%	-42.99%	-2.11%
Net Income Growth	148.42%	150.00%	187.02%	-93.46%	-16.30%	-82.33%	-307.86%	53.57%	-43.23%	-58.72%	-40.99%
EPS Growth	142.86%	166.67%	185.00%	-92.86%	-16.00%	-83.33%	-300.00%	55.56%	-43.18%	-58.14%	-37.50%
Operating Cash Flow Growth	278.28%	-90.25%	-22.08%	40.47%	82.27%	1,367.90%	251.42%	1,185.77%	2.07%	-112.37%	-379.98%
Free Cash Flow Firm Growth	-849.71%	-1,514.88%	260.49%	181.27%	143.40%	116.51%	76.59%	-11.99%	-0.61%	-387.02%	-183.84%
Invested Capital Growth	40.46%	42.81%	-3.30%	-6.80%	-2.86%	-1.95%	3.29%	11.91%	14.72%	22.40%	18.88%
Revenue Q/Q Growth	12.47%	18.75%	-4.66%	3.78%	5.31%	8.04%	-9.29%	3.82%	0.42%	5.21%	-8.91%
EBITDA Q/Q Growth	101.57%	-2.70%	29.24%	-23.54%	54.96%	913.64%	-95.06%	25.59%	12.08%	44.44%	-28.92%
EBIT Q/Q Growth	182.23%	-19.85%	54.86%	-36.30%	112.76%	210.91%	-128.59%	36.71%	18.65%	88.51%	-45.18%
NOPAT Q/Q Growth	40.23%	30.99%	493.78%	-83.32%	130.97%	1,204.09%	-103.99%	3.32%	30.75%	-3.15%	-29.69%
Net Income Q/Q Growth	555.57%	-54.34%	827.53%	-91.05%	559.73%	115.90%	-169.71%	14.50%	39.28%	86.98%	-48.50%
EPS Q/Q Growth	537.50%	-52.94%	750.00%	-90.48%	600.00%	115.00%	-171.43%	12.00%	38.89%	80.00%	-44.44%
Operating Cash Flow Q/Q Growth	1,302.93%	-75.63%	-55.60%	149.20%	-63.85%	94.81%	-19.96%	223.34%	351.47%	76.73%	-779.67%
Free Cash Flow Firm Q/Q Growth	7.81%	-856.21%	-27.76%	48.86%	73.98%	185.78%	63.42%	20.51%	33.80%	-21.61%	-74.98%
Invested Capital Q/Q Growth	-1.05%	45.11%	2.02%	-4.12%	0.61%	-1.74%	-1.67%	-0.07%	1.55%	3.50%	6.54%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	30.06%	32.94%	32.06%	31.90%	30.24%	31.45%	29.27%	30.06%	30.75%	31.63%	29.52%
EBITDA Margin	15.02%	8.38%	10.23%	7.54%	10.24%	6.96%	0.74%	13.62%	11.26%	10.08%	7.35%
Operating Margin	9.64%	8.26%	6.80%	6.74%	7.57%	6.28%	-0.31%	9.32%	7.55%	6.48%	5.89%
EBIT Margin	11.22%	4.47%	6.63%	4.08%	6.65%	3.29%	-3.21%	10.17%	7.72%	6.54%	3.65%
Profit (Net Income) Margin	6.00%	1.03%	2.68%	0.28%	3.19%	0.51%	-3.46%	4.51%	4.09%	2.95%	1.66%
Tax Burden Percent	70.33%	65.83%	72.51%	11.74%	65.04%	35.74%	66.91%	53.63%	66.49%	59.54%	71.18%
Interest Burden Percent	76.04%	34.97%	55.73%	57.49%	73.85%	43.35%	161.55%	82.66%	79.60%	75.71%	63.85%
Effective Tax Rate	29.67%	34.17%	27.49%	88.26%	34.96%	64.26%	0.00%	46.37%	33.51%	40.46%	28.82%
Return on Invested Capital (ROIC)	10.21%	7.58%	7.89%	1.23%	7.38%	3.34%	-0.33%	7.63%	7.76%	6.19%	6.79%
ROIC Less NNEP Spread (ROIC-NNEP)	9.70%	5.03%	6.38%	0.87%	6.23%	2.23%	-2.27%	7.29%	7.13%	5.56%	5.08%
Return on Net Nonoperating Assets (RNNOA)	18.89%	10.38%	9.31%	1.23%	9.09%	3.23%	-3.27%	9.84%	9.61%	7.70%	7.06%
Return on Equity (ROE)	29.10%	17.97%	17.20%	2.46%	16.47%	6.57%	-3.60%	17.48%	17.36%	13.89%	13.84%
Cash Return on Invested Capital (CROIC)	-26.08%	-29.38%	9.23%	8.84%	7.37%	6.53%	1.73%	-4.47%	-6.59%	-12.59%	-8.27%
Operating Return on Assets (OROA)	11.64%	4.38%	7.19%	4.25%	6.83%	3.34%	-3.27%	10.45%	8.03%	7.02%	3.93%
Return on Assets (ROA)	6.23%	1.01%	2.90%	0.29%	3.28%	0.52%	-3.54%	4.63%	4.25%	3.16%	1.78%
Return on Common Equity (ROCE)	29.10%	17.97%	17.20%	2.46%	16.47%	6.57%	-3.60%	17.48%	17.36%	13.89%	13.84%
Return on Equity Simple (ROE_SIMPLE)	11.95%	7.83%	6.73%	0.00%	4.87%	5.46%	7.59%	0.00%	10.50%	13.50%	17.70%
Net Operating Profit after Tax (NOPAT)	24	17	13	2.16	13	5.61	-0.51	13	12	9.43	9.74
NOPAT Margin	6.78%	5.44%	4.93%	0.79%	4.92%	2.24%	-0.22%	5.00%	5.02%	3.86%	4.19%
Net Nonoperating Expense Percent (NNEP)	0.52%	2.55%	1.51%	0.37%	1.15%	1.11%	1.94%	0.34%	0.63%	0.63%	1.71%
Return On Investment Capital (ROIC_SIMPLE)	2.37%	1.68%	-	-	-	0.75%	-	-	-	-	-
Cost of Revenue to Revenue	69.94%	67.06%	67.94%	68.10%	69.76%	68.55%	70.73%	69.94%	69.25%	68.37%	70.48%
SG&A Expenses to Revenue	20.43%	24.68%	25.26%	25.16%	22.67%	25.17%	29.59%	20.74%	23.20%	25.16%	23.64%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	20.43%	24.68%	25.26%	25.16%	22.67%	25.17%	29.59%	20.74%	23.20%	25.16%	23.64%
Earnings before Interest and Taxes (EBIT)	39	14	17	11	17	8.22	-7.42	26	19	16	8.48
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	52	26	27	21	27	17	1.72	35	28	25	17
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.25	3.45	3.53	2.65	1.93	1.69	1.83	1.90	2.18	1.92	1.92
Price to Tangible Book Value (P/TBV)	4.98	5.58	5.67	4.33	3.11	2.76	2.98	3.07	3.66	3.30	3.41
Price to Revenue (P/Rev)	0.73	0.77	0.87	0.67	0.52	0.46	0.51	0.55	0.61	0.53	0.53
Price to Earnings (P/E)	27.21	44.03	52.40	281.14	39.51	30.85	24.12	16.42	20.75	14.22	10.88
Dividend Yield	2.25%	2.29%	2.13%	2.86%	3.74%	4.26%	3.89%	3.63%	3.28%	3.77%	3.84%
Earnings Yield	3.67%	2.27%	1.91%	0.36%	2.53%	3.24%	4.15%	6.09%	4.82%	7.03%	9.19%
Enterprise Value to Invested Capital (EV/IC)	1.65	1.65	2.02	1.67	1.38	1.28	1.34	1.37	1.47	1.37	1.38
Enterprise Value to Revenue (EV/Rev)	1.28	1.39	1.24	1.03	0.91	0.85	0.91	0.95	1.02	0.94	0.92
Enterprise Value to EBITDA (EV/EBITDA)	12.14	15.35	14.16	15.79	11.23	10.30	10.05	8.92	10.68	8.77	7.77
Enterprise Value to EBIT (EV/EBIT)	18.73	25.72	23.95	35.74	20.50	18.35	16.67	13.39	16.93	13.10	11.05
Enterprise Value to NOPAT (EV/NOPAT)	25.44	32.95	33.76	89.21	30.49	27.83	27.47	21.44	22.12	19.96	16.65
Enterprise Value to Operating Cash Flow (EV/OCF)	17.44	27.67	15.43	12.02	11.42	11.30	22.18	69.79	0.00	0.00	51.76
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	21.49	18.23	18.47	19.46	78.76	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	2.73	3.05	1.83	1.90	1.80	1.75	1.77	1.68	1.77	1.77	1.78
Long-Term Debt to Equity	2.67	2.99	1.81	1.79	1.69	1.66	1.68	1.60	1.71	1.72	1.72
Financial Leverage	1.95	2.06	1.46	1.42	1.46	1.45	1.44	1.35	1.35	1.38	1.39
Leverage Ratio	4.28	4.36	3.63	3.62	3.58	3.59	3.57	3.49	3.49	3.57	3.60
Compound Leverage Factor	3.26	1.53	2.02	2.08	2.65	1.56	5.77	2.89	2.78	2.70	2.30
Debt to Total Capital	73.22%	75.32%	64.72%	65.54%	64.27%	63.68%	63.88%	62.70%	63.87%	63.96%	64.00%
Short-Term Debt to Total Capital	1.64%	1.63%	1.02%	4.00%	3.94%	3.49%	3.19%	2.94%	2.05%	2.07%	2.11%
Long-Term Debt to Total Capital	71.59%	73.69%	63.69%	61.54%	60.33%	60.19%	60.68%	59.75%	61.83%	61.89%	61.89%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	26.78%	24.68%	35.28%	34.46%	35.73%	36.32%	36.12%	37.30%	36.13%	36.04%	36.00%
Debt to EBITDA	5.80	7.52	5.18	7.32	6.01	5.83	5.44	4.56	5.15	4.57	4.09
Net Debt to EBITDA	5.24	6.85	4.20	5.60	4.79	4.69	4.41	3.78	4.33	3.82	3.34
Long-Term Debt to EBITDA	5.67	7.36	5.10	6.87	5.64	5.51	5.17	4.35	4.99	4.43	3.96
Debt to NOPAT	12.15	16.15	12.35	41.36	16.33	15.76	14.87	10.96	10.68	10.41	8.77
Net Debt to NOPAT	10.98	14.71	10.01	31.65	13.01	12.69	12.06	9.08	8.96	8.70	7.15
Long-Term Debt to NOPAT	11.88	15.80	12.15	38.84	15.32	14.89	14.13	10.45	10.33	10.07	8.48
Altman Z-Score	2.24	2.13	2.76	2.47	2.37	2.27	2.29	2.44	2.48	2.39	2.35
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.91	3.20	3.23	2.94	3.16	3.12	3.39	3.33	3.54	3.47	3.30
Quick Ratio	1.01	1.11	1.42	1.39	1.37	1.30	1.39	1.39	1.39	1.37	1.33
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-242	-263	35	48	32	19	-22	-59	-74	-112	-92
Operating Cash Flow to CapEx	557.11%	39.33%	131.71%	217.48%	117.23%	287.96%	216.68%	185.82%	79.15%	-25.35%	-46.16%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	7.06	0.00	0.00	0.00	-19.24	-28.96	-30.16
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	2.49	0.00	0.00	0.00	1.62	-0.64	-3.49
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.37	0.00	0.00	0.00	-0.43	-3.17	-11.04
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.04	0.98	1.08	1.04	1.03	1.02	1.02	1.03	1.04	1.07	1.08
Accounts Receivable Turnover	6.64	6.46	6.75	6.11	6.37	6.49	6.69	5.93	6.32	6.61	6.78
Inventory Turnover	2.23	2.11	2.60	2.59	2.42	2.37	2.43	2.53	2.50	2.60	2.67
Fixed Asset Turnover	4.43	4.11	5.24	5.10	5.11	5.08	5.24	5.42	5.57	5.71	5.78
Accounts Payable Turnover	7.60	8.11	8.77	8.84	8.80	8.19	8.21	8.02	8.20	8.39	8.64
Days Sales Outstanding (DSO)	54.96	56.50	54.05	59.70	57.30	56.21	54.55	61.59	57.71	55.26	53.86
Days Inventory Outstanding (DIO)	163.90	172.80	140.25	140.77	150.60	153.71	150.43	144.12	146.07	140.33	136.63
Days Payable Outstanding (DPO)	48.06	44.99	41.63	41.29	41.47	44.57	44.48	45.50	44.53	43.51	42.22
Cash Conversion Cycle (CCC)	170.81	184.31	152.67	159.18	166.42	165.36	160.50	160.21	159.25	152.08	148.27
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	923	933	643	630	657	653	665	676	677	666	644
Invested Capital Turnover	1.51	1.39	1.60	1.56	1.50	1.49	1.49	1.53	1.54	1.61	1.62
Increase / (Decrease) in Invested Capital	266	280	-22	-46	-19	-13	21	72	87	122	102
Enterprise Value (EV)	1,522	1,537	1,296	1,053	907	839	892	929	997	913	887
Market Capitalization	865	851	912	679	520	457	500	535	593	515	506
Book Value per Share	$6.57	$6.09	$6.38	$6.34	$6.67	$6.69	$6.74	$6.97	$6.72	$6.63	$6.49
Tangible Book Value per Share	$4.29	$3.76	$3.98	$3.88	$4.13	$4.08	$4.14	$4.30	$4.00	$3.85	$3.66
Total Capital	993	1,000	733	745	756	746	756	757	754	745	730
Total Debt	727	753	474	488	486	475	483	475	481	476	467
Total Long-Term Debt	711	737	467	458	456	449	459	453	466	461	452
Net Debt	657	686	384	373	387	382	392	394	404	398	381
Capital Expenditures (CapEx)	7.75	7.82	9.58	13	9.73	11	7.48	11	7.91	9.82	23
Debt-free, Cash-free Net Working Capital (DFCFNWC)	455	462	312	312	339	332	345	351	358	351	327
Debt-free Net Working Capital (DFNWC)	526	529	401	427	438	425	436	432	436	430	413
Net Working Capital (NWC)	510	513	394	397	408	399	412	410	420	414	398
Net Nonoperating Expense (NNE)	2.69	14	5.86	1.41	4.55	4.34	7.51	1.25	2.29	2.22	5.88
Net Nonoperating Obligations (NNO)	657	686	384	373	387	382	392	394	404	398	381
Total Depreciation and Amortization (D&A)	13	12	9.37	9.46	9.46	9.17	9.13	8.79	8.68	8.68	8.60
Debt-free, Cash-free Net Working Capital to Revenue	38.25%	41.78%	29.76%	30.66%	33.93%	33.85%	35.33%	35.87%	36.64%	36.12%	34.03%
Debt-free Net Working Capital to Revenue	44.16%	47.84%	38.34%	41.92%	43.81%	43.27%	44.66%	44.18%	44.53%	44.19%	43.02%
Net Working Capital to Revenue	42.79%	46.37%	37.63%	39.00%	40.83%	40.62%	42.19%	41.90%	42.96%	42.60%	41.41%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.52	$0.08	$0.17	$0.02	$0.21	$0.03	($0.20)	$0.28	$0.25	$0.18	$0.10
Adjusted Weighted Average Basic Shares Outstanding	40.52M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M
Adjusted Diluted Earnings per Share	$0.51	$0.08	$0.17	$0.02	$0.21	$0.03	($0.20)	$0.28	$0.25	$0.18	$0.10
Adjusted Weighted Average Diluted Shares Outstanding	40.71M	40.72M	40.58M	40.52M	40.52M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	40.53M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M	40.50M
Normalized Net Operating Profit after Tax (NOPAT)	24	17	13	13	13	11	-0.51	13	12	9.43	9.74
Normalized NOPAT Margin	6.78%	5.44%	4.93%	4.72%	4.92%	4.40%	-0.22%	5.00%	5.02%	3.86%	4.19%
Pre Tax Income Margin	8.54%	1.56%	3.69%	2.35%	4.91%	1.43%	-5.18%	8.41%	6.15%	4.95%	2.33%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	3.82	0.00	0.00	0.00	4.90	4.12	2.77
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	2.83	0.00	0.00	0.00	3.19	2.43	3.18
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	1.70	0.00	0.00	0.00	2.86	1.59	-4.79
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.71	0.00	0.00	0.00	1.14	-0.10	-4.38
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	61.17%	100.64%	111.70%	804.72%	147.71%	131.38%	93.76%	59.63%	67.99%	53.64%	41.81%
Augmented Payout Ratio	61.17%	100.64%	111.70%	804.72%	147.71%	131.38%	93.76%	59.63%	67.99%	53.64%	41.81%

Frequently Asked Questions About Phibro Animal Health's Financials

When does Phibro Animal Health's financial year end?

According to the most recent income statement we have on file, Phibro Animal Health's fiscal year ends in June. Their fiscal year 2024 ended on June 30, 2024.

How has Phibro Animal Health's net income changed over the last 10 years?

Phibro Animal Health's net income appears to be on a downward trend, with a most recent value of $2.42 million in 2024, falling from -$3.13 million in 2014. The previous period was $32.61 million in 2023. Check out Phibro Animal Health's forecast to explore projected trends and price targets.

What is Phibro Animal Health's operating income?

Phibro Animal Health's total operating income in 2024 was $53.32 million, based on the following breakdown:

Total Gross Profit: $313.09 million
Total Operating Expenses: $259.78 million

How has Phibro Animal Health revenue changed over the last 10 years?

Over the last 10 years, Phibro Animal Health's total revenue changed from $691.91 million in 2014 to $1.02 billion in 2024, a change of 47.1%.

How much debt does Phibro Animal Health have?

Phibro Animal Health's total liabilities were at $725.54 million at the end of 2024, a 5.3% increase from 2023, and a 58.7% increase since 2014.

How much cash does Phibro Animal Health have?

In the past 10 years, Phibro Animal Health's cash and equivalents has ranged from $11.82 million in 2014 to $74.25 million in 2022, and is currently $70.61 million as of their latest financial filing in 2024.

How has Phibro Animal Health's book value per share changed over the last 10 years?

Over the last 10 years, Phibro Animal Health's book value per share changed from 0.39 in 2014 to 6.34 in 2024, a change of 1,522.6%.

Related Companies

This page (NASDAQ:PAHC) was last updated on 5/31/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Phibro Animal Health (PAHC) Financials

Frequently Asked Questions About Phibro Animal Health's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Phibro Animal Health (PAHC) Financials

Annual Income Statements for Phibro Animal Health

Quarterly Income Statements for Phibro Animal Health

Annual Cash Flow Statements for Phibro Animal Health

Quarterly Cash Flow Statements for Phibro Animal Health

Annual Balance Sheets for Phibro Animal Health

Quarterly Balance Sheets for Phibro Animal Health

Annual Metrics And Ratios for Phibro Animal Health

Quarterly Metrics And Ratios for Phibro Animal Health

Frequently Asked Questions About Phibro Animal Health's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools